Cidara治疗 CDTX 深 沪
已收盘 12-19 16:00:00 美东时间
220.6901
+0.340
+0.15%
华盛通- 最 高221.20
- 今 开220.39
- 成交量 59.20万股
- 最 低 219.36
- 昨 收 220.35
- 总市值 152.39亿
- 52周最高 221.20
- 市盈率 静 --
- 换手率 0.86%
- 52周最低 15.22
- 委 比 80.91%
- 总股本 6904.95万
- 历史最高 221.20
- 量 比 0.61
- 振 幅 0.84%
- 历史最低 0.00
- 每 手 1
- 风险率 57.98%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cidara Therapeutics Reaches Target Enrollment Of Phase 3 ANCHOR Trial Evaluating CD388
Target enrollment of 6,000 participants completed in the Northern HemispherePlanned interim analysis in Q1 2026 will determine potential need for additional enrollment during Southern Hemisphere flu season
11-24 21:08
Pfizer's New mRNA Flu Vaccine Outperforms Traditional Shot Against Predominant Strains
Pfizer-funded study finds a next-gen mRNA flu shot works better against current strains — but causes more short-term side effects.
11-21 23:48
Guggenheim Downgrades Cidara Therapeutics to Neutral
Guggenheim analyst Seamus Fernandez downgrades Cidara Therapeutics (NASDAQ:CDTX) from Buy to Neutral.
11-18 22:06
Gold Tumbles Over 2%; Cidara Therapeutics Shares Spike Higher
U.S. stocks traded mixed midway through trading, with the Dow Jones index falli...
11-15 01:02
Merck Makes Big Bet On Flu Protection With Cidara Buyout
Merck (NYSE: MRK) to acquire Cidara (NASDAQ: CDTX) for $9.2 billion, diversifying its portfolio with CD388.
11-14 22:32
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Cidara Therapeutics Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza
Cidara Therapeutics' Phase 2b NAVIGATE trial for CD388 met its primary and all secondary endpoints, showing 76%, 61%, and 58% protection against influenza for 450mg, 300mg, and 150mg doses respectively, with no safety signals. The company plans an End of Phase 2 meeting with the FDA and aims to initiate a Phase 3 trial.
06-23 11:00
Needham Reiterates Buy on Cidara Therapeutics, Maintains $35 Price Target
Needham analyst Joseph Stringer reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Buy and maintains $35 price target.
03-07 20:46
Cidara Therapeutics Restructures Workforce By 30% To Focus On Planned Clinical Development Of CD388
Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care
2024-09-13 04:09
